Ralf Stemkens

Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment

Sanne M.H. Zweijpfenning, Rob E. Aarnoutse, Martin J. Boeree et al. · CHEST Journal · 2023 · 30 citations · Full text

Health Sciences, Medicine, Respiratory Infection +10

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial

Norbert Heinrich, Veronique de Jager, Julia Dreisbach et al. · The Lancet Microbe · 2025 · 16 citations · Full text

Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment

Ralf Stemkens, Carlijn H. C. Litjens, Sofiati Dian et al. · International Journal of Antimicrobial Agents · 2019 · 13 citations · Full text

Tuberculous Meningitis Treatment, Initial Phase, Pulmonary Tuberculosis +7

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Ralf Stemkens, Veronique de Jager, Rodney Dawson et al. · Antimicrobial Agents and Chemotherapy · 2023 · 13 citations · Full text

Clofazimine as a substitute for rifampicin improves efficacy of <i>Mycobacterium avium</i> pulmonary disease treatment in the hollow-fiber model

Sandra Salillas, J. A. M. Raaijmakers, Rob E. Aarnoutse et al. · Antimicrobial Agents and Chemotherapy · 2024 · 12 citations · Full text